Innovator’s Pitch Challenge

Vote for Us

Interested in Connecting? Please contact:
Ethan Mann, PhD, MBA
CEO
Ethan.Mann@ValidusTherapeutics.com

Message the company or request a 1:1 meeting here

For patients and doctors battling resistant infections, Validus Cellular Therapeutics is developing VCT-001, a novel preclinical stage anti-infective therapy unlike current small molecule antibiotics which are susceptible to resistance and are limited accessing infections. VCT-001 is an allogeneic cell therapy to be given with standard of care antibiotic regimens to successfully treat infections.